Pemvidutide had a strong 2024 research year. MOMENTUM (phase 2 obesity, 48 weeks) and IMPACT MASH (phase 2b, 24 weeks) both delivered positive top-line results. Phase 3 obesity trial design is in planning, MASH phase 3 is closer, and Altimmune is exploring additional indications including alcohol use disorder. This article walks through what’s published, what’s coming, and how pemvidutide fits the broader pipeline.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
MOMENTUM was a phase 2, 391-patient, 48-week randomized double-blind placebo-controlled trial of pemvidutide 1.2, 1.8, and 2.4 mg weekly versus placebo in adults with obesity (mean BMI 37).<\/strong> Top-line results published in 2024 showed:<\/p>\n Quick Answer: MOMENTUM (phase 2 obesity): 15.6% weight loss at 2.4 mg, 48 weeks<\/p>\n Mean body weight loss: 10.3% (1.2 mg), 11.2% (1.8 mg), 15.6% (2.4 mg), 2.2% (placebo).<\/p>\n About 22% of 2.4 mg patients lost 20% or more of baseline weight.<\/p>\n About 78% of weight lost at 2.4 mg was fat mass, 22% lean mass (favorable versus pure GLP-1 trials).<\/p>\n Liver fat fell substantially across doses (a secondary endpoint).<\/p>\n GI side effects dominated the AE profile, similar in pattern to other GLP-1 drugs.<\/p>\n Importantly, the weight loss curve had not plateaued at 48 weeks. The drug’s full efficacy ceiling isn’t yet known.<\/p>\n IMPACT MASH was a phase 2b, 212-patient, 24-week randomized trial in adults with biopsy-confirmed MASH (F1 to F3 fibrosis).<\/strong> Top-line results from June 2024:<\/p>\n MASH resolution without worsening fibrosis: 59.1% on 1.2 mg, 52.1% on 1.8 mg, 43.5% on 2.4 mg, 19.1% on placebo.<\/p>\n MRI-PDFF liver fat: down 57.1% on 1.2 mg, 58.5% on 1.8 mg.<\/p>\n Liver enzymes (ALT, AST) improved across doses.<\/p>\n Fibrosis improvement was not statistically significant at 24 weeks (typical for the short duration; fibrosis usually needs 52 to 72 weeks).<\/p>\n The 1.2 mg dose unexpectedly outperformed higher doses on the MASH resolution endpoint. The mechanism is likely related to glucagon receptor desensitization at higher doses, but it’s still being investigated.<\/p>\n Altimmune has announced plans for phase 3 obesity trials but specific protocols haven’t been published in detail.<\/strong> Standard phase 3 obesity programs run 68 to 72 weeks with primary endpoints of mean weight loss and percentage of patients losing 5% or more, and recruit several thousand participants.<\/p>\n Phase 3 MASH design is also in development. Typical MASH phase 3 trials require liver biopsy at baseline and 72 weeks, with primary endpoints of MASH resolution without fibrosis worsening or fibrosis improvement without worsening MASH.<\/p>\n Estimated phase 3 timelines depend on FDA feedback. If trials begin dosing in 2025 to early 2026, primary readouts could come in 2027 to 2028. Regulatory filing could follow in 2028, with approval possibly 2028 to 2029 at earliest.<\/p>\n The current GLP-1-based obesity pipeline includes:<\/p>\n Retatrutide (Eli Lilly): triple agonist GLP-1\/GIP\/glucagon. Phase 2 data (Jastreboff 2023 NEJM) showed 24.2% weight loss at 48 weeks at 12 mg. Phase 3 (TRIUMPH program) is ongoing.<\/p>\n Survodutide (Boehringer Ingelheim\/Zealand): GLP-1\/glucagon dual agonist. Phase 2 obesity showed about 18.7% at 46 weeks.<\/p>\n CagriSema (Novo Nordisk): semaglutide plus cagrilintide (amylin analog). Phase 3 (REDEFINE 1) reported 22.7% at 68 weeks in late 2024.<\/p>\n Orforglipron (Eli Lilly): oral small-molecule GLP-1 agonist. Phase 3 ongoing.<\/p>\n Pemvidutide sits in the middle of this pack on raw weight loss magnitude but has the unique combination of meaningful liver fat effects and lean mass preservation, which positions it well for MASH and possibly for sarcopenic obesity in older adults.<\/p>\n Animal studies have shown GLP-1 receptor agonists, especially dual agonists like pemvidutide, can reduce alcohol intake.<\/strong> The mechanism appears to involve modulation of dopamine pathways in the reward system, similar to how GLP-1 drugs reduce food craving.<\/p>\n Human studies are mostly observational so far. Patients on semaglutide and tirzepatide for diabetes or obesity have reported reduced alcohol intake in surveys and small open-label studies. Randomized trials specifically for alcohol use disorder are early but ongoing for the GLP-1 class generally.<\/p>\n Whether pemvidutide will pursue a formal alcohol use disorder indication isn’t confirmed. Altimmune has signaled interest in exploring this area.<\/p>\n No dedicated cardiovascular outcomes trial (CVOT) has been announced for pemvidutide.<\/strong> Class effects from semaglutide (SELECT, Lincoff et al. 2023 NEJM, 20% MACE reduction) suggest GLP-1 drugs broadly benefit cardiovascular outcomes in high-risk patients.<\/p>\n The glucagon receptor component adds uncertainty. Glucagon-driven heart rate increases and LDL increases could theoretically offset some of the GLP-1 cardiovascular benefit. A CVOT would be needed to know.<\/p>\n CVOTs typically run 3 to 5 years and recruit 8,000 to 20,000 patients. They’re expensive ($300 million plus) but valuable for label expansion. Whether Altimmune commits to one for pemvidutide depends on partner strategy and commercial outlook.<\/p>\n No pediatric pemvidutide trials have been announced.<\/strong> Wegovy\u00ae is approved for adolescents 12 and older based on the STEP TEENS trial (Kelly et al. 2022 NEJM). Pediatric pemvidutide development would follow the adult phase 3 program, likely 2 to 3 years behind.<\/p>\n The realistic earliest pemvidutide approval timeline:<\/p>\n 2025 to early 2026: Phase 3 trials begin.<\/p>\n 2027 to 2028: Phase 3 primary readouts.<\/p>\n Late 2028 to 2029: FDA filing for obesity and possibly MASH.<\/p>\n 2029 to 2030: Approval, if all goes well.<\/p>\n Delays are common. Phase 3 trial enrollment can take longer than projected, especially given competition from other GLP-1 drugs for the same patient population. Manufacturing scale-up and regulatory back-and-forth can add additional time.<\/p>\n Hard to predict. The supply situation for GLP-1 drugs has been driven by demand outpacing manufacturer capacity. Pemvidutide will face similar demand pressures at launch, especially if priced competitively.<\/p>\n If Altimmune partners with a large pharma manufacturer for commercial production, supply may be adequate. If they go it alone, shortages are more likely. Shortage status would open the door for FDA-permitted compounding, which would dramatically affect market dynamics.<\/p>\n Research on GLP-1\/glucagon dual agonism is exploring the optimal receptor activity ratio for different patient populations.<\/strong> Higher glucagon activity may favor MASH and possibly NAFLD; higher GLP-1 activity favors raw weight loss in patients without significant liver disease.<\/p>\n Pemvidutide’s relatively balanced 1:1 functional ratio sits between cotadutide (more GLP-1 weighted, discontinued) and survodutide (also more GLP-1 weighted). Future molecules may push toward even more glucagon-heavy ratios for specific MASH applications.<\/p>\n Mechanism studies are also exploring how dual agonism affects sympathetic nervous system activity, energy expenditure, and substrate utilization at the level of individual tissues (muscle, liver, adipose).<\/p>\n The pipeline includes combinations like CagriSema (semaglutide + cagrilintide), MariTide (Amgen’s GIP antagonist + GLP-1), and various amylin analog combinations.<\/strong> Adding amylin agonism on top of dual agonism (GLP-1\/glucagon\/amylin or even quadruple agonism) is being explored.<\/p>\n Pemvidutide’s combination potential is open. Pairing it with cagrilintide or another amylin analog could compound weight loss while preserving liver and lean mass benefits.<\/p>\n Based on current data, the highest-benefit pemvidutide candidates appear to be:<\/p>\n Adults with obesity plus MASH or significant hepatic steatosis. Adults seeking weight loss with concerns about lean mass loss (older adults, athletes). Adults without type 2 diabetes (the flat HbA1c profile means no diabetes benefit but no harm). Adults at metabolic risk without established cardiovascular disease (until CVOT data exists).<\/p>\n For diabetes patients, semaglutide or tirzepatide remain better choices. For pure aggressive weight loss without other concerns, tirzepatide or retatrutide may produce more weight loss.<\/p>\n TrimRx currently offers compounded semaglutide and tirzepatide through telehealth.<\/strong> Pemvidutide isn’t on the formulary because it isn’t FDA-approved. The free assessment quiz routes patients to the right approved option based on history and goals.<\/p>\n When pemvidutide is approved, TrimRx will evaluate carrying it under standard medical oversight. Until then, the personalized treatment plan focuses on the available GLP-1 options.<\/p>\n Key Takeaway: Phase 3 obesity trial planning underway; first dosing expected 2025 to 2026<\/p>\n Several important questions need phase 3 data:<\/p>\n What’s the maximum weight loss ceiling with longer treatment (72 weeks)? Does the lean mass preservation hold up in larger samples? Does pemvidutide reduce major cardiovascular events the way semaglutide does? Is there a fibrosis improvement signal at 52 to 72 weeks in MASH? What are the long-term effects of mild LDL increases? Does the 1.2 mg dose’s surprising MASH advantage replicate?<\/p>\n Phase 3 trials will start to answer these in the late 2020s.<\/p>\n Pemvidutide may have applications beyond obesity and MASH:<\/p>\n Type 2 diabetes prevention in prediabetic patients with significant adiposity.<\/p>\n Chronic kidney disease (class effects from FLOW suggest GLP-1 drugs may benefit; pemvidutide’s effect is unstudied).<\/p>\n Sleep apnea (SURMOUNT-OSA approved tirzepatide for OSA in Dec 2024; pemvidutide may follow given the weight loss).<\/p>\n Heart failure with preserved ejection fraction (STEP-HFpEF showed semaglutide benefit; pemvidutide hasn’t been tested).<\/p>\n Polycystic ovary syndrome (PCOS), which has substantial overlap with obesity and insulin resistance.<\/p>\n Phase 1 single-ascending-dose and multiple-ascending-dose studies in healthy volunteers established the pharmacokinetic profile, including the six-day half-life and tolerability at doses up to 2.4 mg weekly.<\/strong><\/p>\n Phase 1b studies in patients with obesity established initial efficacy signals: meaningful weight loss over 12 weeks even at modest doses.<\/p>\n These early-stage data justified the phase 2 program that produced MOMENTUM and IMPACT MASH.<\/p>\n Altimmune is a clinical-stage biotech focused on liver disease, obesity, and metabolic disorders.<\/strong> Pemvidutide is the company’s lead asset.<\/p>\n Altimmune’s smaller scale means they may seek partnerships for phase 3 and commercialization. A larger pharma partner could accelerate development and provide marketing reach. Alternatively, Altimmune may stay independent and out-license selectively.<\/p>\n The GLP-1 obesity market is dominated by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide), which combined hold over 90% of the current GLP-1 obesity market.<\/strong><\/p>\n Late-stage challengers include Merck (efinopegdutide), Boehringer Ingelheim (survodutide), and Lilly itself with retatrutide. Several oral and combination products are also in development.<\/p>\n Pemvidutide needs differentiated positioning. The lean mass preservation story and the strong MASH liver fat data are the primary differentiation factors.<\/p>\n Real-world evidence doesn’t exist yet.<\/strong> Post-approval studies will accumulate over the first few years after launch.<\/p>\n For approved GLP-1 drugs, real-world evidence has confirmed clinical trial efficacy with somewhat reduced effect sizes (typically 70 to 85% of trial averages) due to less structured adherence and follow-up.<\/p>\n Class-wide signals for GLP-1 drugs:<\/p>\n Pancreatitis (longstanding class warning, weak evidence in randomized trials).<\/p>\n Gallbladder disease (modest signal during rapid weight loss).<\/p>\n Thyroid cancer (rodent finding, unclear human relevance, boxed warning).<\/p>\n Aspiration during anesthesia (newer concern with delayed gastric emptying).<\/p>\n Mental health (depression, suicidality; investigation ongoing).<\/p>\n Pemvidutide’s surveillance will include the same signals plus any drug-specific findings from large phase 3 trials.<\/p>\n Altimmune’s manufacturing capacity is smaller than larger pharma.<\/strong> Scaling production for a successful obesity drug requires significant investment and lead time.<\/p>\n If pemvidutide demand at launch exceeds Altimmune’s capacity, shortages are likely. Shortage status would open the door for FDA-permitted compounding.<\/p>\n A larger pharma partnership could solve the manufacturing challenge but may not come together before launch.<\/p>\n TrimRx is positioned to evaluate adding new GLP-1 drugs to its formulary as they become approved and clinically relevant.<\/strong> The free assessment quiz and personalized treatment plan can integrate pemvidutide (and efinopegdutide, retatrutide, etc.) into clinical recommendations once available.<\/p>\n For 2026 to 2028, the practical TrimRx GLP-1 options remain compounded semaglutide and tirzepatide. Approved options will expand over the rest of the decade as pipeline drugs reach market.<\/p>\n Adding amylin agonism on top of pemvidutide’s dual agonism is a theoretical next step.<\/strong> An amylin analog combined with a dual GLP-1\/glucagon agonist could compound effects on appetite, energy expenditure, and liver fat.<\/p>\n Whether Altimmune pursues such combinations isn’t public. Other pipeline molecules in this space include various amylin analogs and combinations.<\/p>\n Long-term outcomes (cardiovascular events, kidney events, mortality) require trials lasting 3 to 5 years.<\/strong> No long-term outcomes data exists for pemvidutide. Class effects suggest benefit but direct evidence is years away.<\/p>\n No OSA trial has been run for pemvidutide.<\/strong> Weight loss alone improves OSA in many patients. Tirzepatide gained the SURMOUNT-OSA indication in Dec 2024.<\/p>\n Earliest realistic FDA approval is 2028 to 2029, contingent on phase 3 trial success and regulatory review.<\/p>\n The favorable lean mass preservation (22% of weight lost as lean mass vs. typical 25 to 40% for pure GLP-1 drugs) was a meaningful surprise.<\/p>\n No. HbA1c stays flat. Pemvidutide is designed for obesity and MASH, not diabetes.<\/p>\n Different molecules, different profiles. Retatrutide produced larger weight loss in phase 2 (24.2% at 48 weeks) but pemvidutide has stronger liver fat data and better lean mass preservation.<\/p>\n Long-term (multi-year) pemvidutide safety data doesn’t exist yet. The class as a whole has good multi-year data. Phase 3 trials will accumulate longer follow-up.<\/p>\n After FDA approval and TrimRx evaluation, which puts the earliest availability around 2029 or later.<\/p>\n Likely priced similar to current brand GLP-1 drugs ($1,000 to $1,500\/month) at launch, with manufacturer savings programs available. Compounded equivalents probably won’t exist for at least a year or two after launch.<\/p>\n No direct evidence yet. Class effects from FLOW (semaglutide kidney trial) suggest GLP-1 drugs may benefit CKD patients. Pemvidutide’s glucagon component is theoretically less protective for kidneys but not necessarily worse.<\/p>\n The favorable lean mass preservation pattern in phase 2 suggests pemvidutide may be especially useful in older adults concerned about sarcopenia during weight loss. Phase 3 trials should provide clearer data.<\/p>\n Search clinicaltrials.gov for “pemvidutide” or “Altimmune” to find currently recruiting studies. Eligibility criteria vary by trial; common requirements include BMI thresholds, age ranges, and exclusion of major comorbidities.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Pemvidutide had a strong 2024 research year.<\/p>\n","protected":false},"author":11,"featured_media":93238,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Pemvidutide Latest Research: New Indications, Trials & What's Coming","_yoast_wpseo_metadesc":"Pemvidutide had a strong 2024 research year. MOMENTUM (phase 2 obesity, 48 weeks) and IMPACT MASH (phase 2b, 24 weeks) both delivered positive top-line...","_yoast_wpseo_focuskw":"pemvidutide latest research","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[41],"class_list":["post-90421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-research"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90421"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90421\/revisions"}],"predecessor-version":[{"id":92490,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90421\/revisions\/92490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93238"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Did IMPACT MASH Show?<\/h2>\n
What Phase 3 Trials Are Planned?<\/h2>\n
How Does Pemvidutide Compare to the Rest of the Pipeline?<\/h2>\n
What About Alcohol Use Disorder?<\/h2>\n
What About Cardiovascular Outcomes?<\/h2>\n
Are There Pediatric Trials?<\/h2>\n
What’s the Regulatory Timeline?<\/h2>\n
Will Pemvidutide Be on Shortage Like Semaglutide?<\/h2>\n
What New Science Is Emerging on Dual Agonism?<\/h2>\n
What About Combination Therapies?<\/h2>\n
What Patient Populations Might Benefit Most as Data Evolves?<\/h2>\n
How Does TrimRx Position Around Pemvidutide?<\/h2>\n
What Scientific Questions Remain Open?<\/h2>\n
What Other Research Areas Are Worth Watching?<\/h2>\n
What Earlier Studies Built the Case for Pemvidutide?<\/h2>\n
What Does the Altimmune Company Strategy Look Like?<\/h2>\n
What Competitive Pressures Affect Pemvidutide’s Path?<\/h2>\n
What About Real-world Evidence for Pemvidutide?<\/h2>\n
What Pharmacovigilance Signals Are Being Watched?<\/h2>\n
What About Manufacturing and Supply Concerns?<\/h2>\n
How Does This Fit the TrimRx Future Plan?<\/h2>\n
How Might Combinations Involving Pemvidutide Develop?<\/h2>\n
What About Long-term Outcomes Data?<\/h2>\n
What About Sleep Apnea Applications?<\/h2>\n
FAQ<\/h2>\n
When Will Pemvidutide Be Approved?<\/h3>\n
What’s the Most Surprising Finding From MOMENTUM?<\/h3>\n
Will Pemvidutide Work for Diabetes?<\/h3>\n
Is Pemvidutide Better Than Retatrutide?<\/h3>\n
What About Long-term Safety?<\/h3>\n
When Might I See Pemvidutide at TrimRx?<\/h3>\n
Will Pemvidutide Be Cheaper or More Expensive Than Current Options?<\/h3>\n
Will Pemvidutide Help with Kidney Disease?<\/h3>\n
Is Pemvidutide Good for Older Adults?<\/h3>\n
What Clinical Trials Are Recruiting Now?<\/h3>\n